BioMarin Buys Alesta for ALE1, First Oral Hypophosphatasia Therapy
BMRN sits 36% above its 52-week low of $49.259.
Summary
BioMarin is acquiring Alesta Therapeutics to gain ALE1, a potential first oral therapy for hypophosphatasia. The deal includes a $275 million upfront payment, plus up to $215 million in development and regulatory milestone payments, and a $22 million indemnification escrow. Alesta will spin out all non-ALE1 assets to a new entity, and Alesta employees will transfer to the spinout entity prior to close; no Alesta employees will become BioMarin employees. The transaction is expected to close in Q3 2026 and have a modestly dilutive impact on 2026 financial results. The acquisition adds a clinical-stage program to BioMarin's pipeline, expanding its rare disease portfolio beyond Voxzogo and the Amicus deal, and follows strong Q2 results and raised guidance. The deal is strategically significant for a company with a $12.9B market cap.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 8-K discloses up to $215 million in development and regulatory milestone payments, a $22 million indemnification escrow, and a Q3 2026 expected closing.
At the time of this announcement, BMRN was trading at $67.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.